{
    "clinical_study": {
        "@rank": "40066", 
        "arm_group": {
            "arm_group_label": "All participants", 
            "description": "Previous treatment with onabotulinumtoxinA for Chronic Migraine based on retrospective review of medical records."
        }, 
        "brief_summary": {
            "textblock": "This study will  evaluate the effectiveness of OnabotulinumtoxinA to prevent headaches in\n      patients with Chronic Migraine."
        }, 
        "brief_title": "A Retrospective Study to Evaluate the Effectiveness of onabotulinumtoxinA in Preventing Headaches in Patients With Chronic Migraines", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Migraine, Headache", 
        "condition_browse": {
            "mesh_term": [
                "Headache", 
                "Migraine Disorders"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  History of chronic migraines\n\n          -  15 or more headache days over a 30 day period\n\n          -  A minimum of 2 consecutive treatment cycles of 100 units onabotulinumtoxinA and a\n             minimum of 2 consecutive treatment cycles with the onabotulinumtoxinA dosing between\n             155 and 195 units\n\n        Exclusion Criteria:\n\n          -  Any treatment cycle dose of onabotulinumtoxinA greater than 200 units"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Participants with chronic migraines who received a minimum of two consecutive treatment\n        cycles of 100 units onabotulinumtoxinA and a minimum of two consecutive treatment cycles\n        with the OnabotulinumtoxinA dosing between 155 and 195 units."
            }
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01749423", 
            "org_study_id": "GMA-BTX-CM-12-518"
        }, 
        "intervention": {
            "arm_group_label": "All participants", 
            "description": "Previous treatment with onabotulinumtoxinA for Chronic Migraine.", 
            "intervention_name": "OnabotulinumtoxinA", 
            "intervention_type": "Biological", 
            "other_name": [
                "botulinum toxin Type A", 
                "BOTOX\u00ae"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Botulinum Toxins, Type A", 
                "Botulinum Toxins"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 31, 2014", 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of Headache Days", 
            "safety_issue": "No", 
            "time_frame": "Up to 56 Weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01749423"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014", 
        "why_stopped": "Company decision due to enrollment challenges."
    }
}